Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of “Buy” from Brokerages

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have earned an average rating of “Buy” from the eight analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $8.80.

A number of research analysts have recently issued reports on AQST shares. Lake Street Capital set a $6.00 price objective on Aquestive Therapeutics in a research note on Tuesday, February 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Monday, April 20th. Oppenheimer began coverage on Aquestive Therapeutics in a research note on Friday, April 24th. They issued an “outperform” rating and a $8.00 price objective on the stock. Finally, Wall Street Zen raised Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th.

Insider Buying and Selling at Aquestive Therapeutics

In related news, CEO Daniel Barber sold 180,677 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $4.17, for a total transaction of $753,423.09. Following the transaction, the chief executive officer directly owned 1,004,753 shares of the company’s stock, valued at approximately $4,189,820.01. This represents a 15.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Cassie Jung sold 45,791 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $4.17, for a total value of $190,948.47. Following the sale, the chief operating officer directly owned 274,980 shares of the company’s stock, valued at $1,146,666.60. This represents a 14.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 403,947 shares of company stock worth $1,685,450 in the last quarter. Company insiders own 6.81% of the company’s stock.

Hedge Funds Weigh In On Aquestive Therapeutics

Several institutional investors have recently modified their holdings of the business. Aberdeen Group plc bought a new position in Aquestive Therapeutics during the third quarter valued at $3,494,000. Blue Owl Capital Holdings LP grew its holdings in Aquestive Therapeutics by 35.9% during the third quarter. Blue Owl Capital Holdings LP now owns 1,250,000 shares of the company’s stock valued at $6,988,000 after purchasing an additional 330,000 shares during the period. Federated Hermes Inc. bought a new position in Aquestive Therapeutics during the third quarter valued at $4,381,000. Oppenheimer & Co. Inc. bought a new position in Aquestive Therapeutics during the third quarter valued at $187,000. Finally, GSA Capital Partners LLP grew its holdings in Aquestive Therapeutics by 29.3% during the third quarter. GSA Capital Partners LLP now owns 241,359 shares of the company’s stock valued at $1,349,000 after purchasing an additional 54,667 shares during the period. 32.45% of the stock is owned by institutional investors.

Aquestive Therapeutics Trading Up 0.4%

NASDAQ AQST opened at $4.04 on Friday. The business’s 50-day moving average price is $4.15 and its two-hundred day moving average price is $4.61. Aquestive Therapeutics has a 12 month low of $2.64 and a 12 month high of $7.55. The firm has a market capitalization of $506.19 million, a PE ratio of -6.61 and a beta of 1.50.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.07. The company had revenue of $14.45 million during the quarter, compared to the consensus estimate of $10.90 million. As a group, analysts forecast that Aquestive Therapeutics will post -0.43 earnings per share for the current fiscal year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.